Status:

COMPLETED

Investigation of Wearing Compliance of Spectacles for Myopia Control

Lead Sponsor:

CooperVision, Inc.

Conditions:

Myopia

Eligibility:

All Genders

6-15 years

Brief Summary

The goal of this observational study was to compare the wearing patterns of spectacles prescribed for myopia control in juvenile wearers.

Detailed Description

This unmasked, multi-center, observational study evaluated the wearing patterns of established (use of ≥3 months) juvenile spectacles wearers. It aimed to compare the wearing patterns of spectacles fo...

Eligibility Criteria

Inclusion

  • They are aged between six and 15 years old.
  • Their parent or guardian understands the rights of the subject and are willing to sign a statement of informed consent.
  • They understand the study at a level appropriate for their age and are willing to sign a statement of assent.
  • They and their parents or guardians are willing and able to follow the protocol.
  • They currently use spectacle lenses for myopia control and have done so for at least three months.
  • They agree not to participate in other clinical research for the duration of this study.

Exclusion

  • They have an unusual ophthalmic history, which in the opinion of the site investigator or Principal Investigator might impact on the successful conduct of the study.
  • They are amblyopic.

Key Trial Info

Start Date :

September 30 2024

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

January 18 2025

Estimated Enrollment :

53 Patients enrolled

Trial Details

Trial ID

NCT06590441

Start Date

September 30 2024

End Date

January 18 2025

Last Update

November 25 2025

Active Locations (4)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (4 locations)

1

Eye2C Ltd

Sale, Cheshire, United Kingdom, M33 7XF

2

Susan Hilton Ltd

Darwen, England, United Kingdom, BB3 2AA

3

Columbo Ltd

Oakwood, Leeds, United Kingdom, LS8 2HU

4

David Gould Opticians Limited

Haslingden, Rossendale, United Kingdom, BB4 5QN